Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Thermoregulation
Interventions: None-placebo; Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Fort Novosel, Alabama • Fort Jackson, South Carolina

Conditions: Schizophrenia
Interventions: AQW051, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Garden Grove, California • Glendale, California • National City, California + 9 more

Conditions: Generalized Myasthenia Gravis
Interventions: Placebo, Cladribine Low Dose, Cladribine High Dose; Other · Drug
Lead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 19 more

Conditions: Type 2 Diabetes
Interventions: MBX-102, Placebo, Actos; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Buena Park, California • Los Angeles, California + 13 more

Conditions: Alzheimer Disease
Interventions: JNJ-64042056, Placebo; Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 55 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more

Conditions: Opioid Use Disorder
Interventions: Cannabidiol 200mg, Epidiolex, Cannabidiol 400mg, Placebo; Drug
Lead sponsor: Yasmin Hurd; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Drinking, Sex Behavior, Men
Interventions: Alcohol, Placebo (non-alcoholic beverage); Drug · Other
Lead sponsor: Syracuse University; Other
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Syracuse, New York • Vermillion, South Dakota

Conditions: Type 1 Diabetes
Interventions: Sitagliptin and Lansoprazole, Placebo; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 11 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota

Conditions: Collagen Synthesis
Interventions: Epicatechin-rich cocoa dose response, Epicatechin-rich cocoa vs placebo on performance; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Davis, California

Conditions: Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions: Bupropion, Behavioral activation therapy, Placebo, Clinical Management; Drug · Behavioral · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Stony Brook, New York • Dallas, Texas • Seattle, Washington

Conditions: Hepatitis C
Interventions: Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 22 more

Conditions: Septic Shock
Interventions: selepressin, placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more

Conditions: Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions: Placebo Oral Tablet, AGB101 220 mg tablet; Drug
Lead sponsor: AgeneBio; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more

Conditions: Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
Interventions: VIS649, Placebo; Biological
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Obesity
Interventions: An alcoholic extract of Artemisia dracunculus L., Placebo; Dietary Supplement · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 30 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Non-small Cell Lung Cancer
Interventions: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 26
States / cities: Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 22 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Glimepiride, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more

Conditions: Alzheimer Disease, Dementia, Prescribing, Off-Label
Interventions: Overprescribing letter to attributed physician, Placebo letter to attributed physician; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 336,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Cambridge, Massachusetts • New York, New York

Conditions: Dermatologic Complications, Malignant Neoplasm, Pain
Interventions: menadione topical lotion, placebo, questionnaire administration, management of therapy complications; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Rochester, Minnesota

Conditions: Knee Osteoarthritis
Interventions: DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Weight Loss, Appetite Loss
Interventions: tDCS, Shame- No current; Device
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetic Neuropathies
Interventions: Placebo, [S,S]-Reboxetine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anniston, Alabama • Birmingham, Alabama • Mission Viejo, California + 24 more

Conditions: Pain, Postoperative
Interventions: XaraColl, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 24
States / cities: Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 19 more

Search by objective public record fields.

Physiological Responses to Heat Stress During High-risk Events

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Investigation of the Pharmacokinetic Profile of CBD

Alcohol and Implicit Process in Sexual Risk Behavior in MSM

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

Effects of Epicatechin-rich Cocoa on Collagen Synthesis

Combination of Novel Therapies for CKD Comorbid Depression

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Safety and Efficacy Study of Tarragon on Insulin Action in Humans

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

Role of Transcranial Direct Current Stimulation in Appetite and Weight Control

A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty